Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEO

Lower than per week after dropping within the trial of the principle court docket that will defend the Wegovy (Semaglutide) from the market competitors, Novo Nordisk decreased gross sales forecast for 2025, which raised the investor concern.

Novo Nordisk, one of many largest capital in Europe, has warned that gross sales progress all year long will likely be 8 % to 14 %, which is a pointy climbing of expectations which have already been decreased by 13 % to 21 %.

The shares within the Danish pharmaceutical maker decreased by 21.7 % to DKK346.9 in the marketplace on July 29 after the announcement. The shares rose by solely 2 % on July 30 at Market Open, which represents the opening of a defeated new day. The diving share has wiped greater than 60 billion euros (69 billion {dollars}) of the corporate’s worth.

The arrows of the Copenhagen Inventory Change have overwhelmed Novo Nordisk to a brand new govt director. It has been emphasised that Maziar Mike DouStdar, at the moment EVP for worldwide operations in Novo, will take the top of a metabolic pathologist. Larse Ferrogeard Juergnain, who has succeeded A crossroads with Novo in May Amid concern that the corporate was leaving its opponents within the weight reduction market. The share value in Novo has steadily decreased since late 2024 as a result of competitors within the area of metabolic ailments.

DouSTDAR will reduce off his work to revive Novo to its physique within the GLP-1RA. Elie Lily took the initiative with Tirzepatide gross sales, partly as a result of its excessive effectiveness. Analysis by Globaldata In January 2025, it was proven that Tirzepatide was exceeding Smaglutide within the weight problems market, as he had greater ceiling forecasts by 2031. Final yr, Eli Lily’s gross sales elevated by 32 % in comparison with 26 % for Nofu Nordsk.

Novo Nordsk blames low progress forecasts in Wigofi within the weight problems market in the USA for its directives for 2025. Low progress forecast for diabetes medication within the US GLP-1RA market, in addition to the low penetration of Wegoz in worldwide markets.

Not solely the low gross sales, Eli Lily – was not eroded by the excessive stent out there for the market share of Novo Nordsk. These alternate options have been cheaper and simpler for sufferers, and the competitors that forces Novo on Reduce the price of Wegovy In the USA. The corporate confirmed that the multiplier steady isn’t secure and unsafe.

“For Wegovy in the USA, gross sales forecast displays the continual use of the GLP-1 automobile, and the market expands is slower than anticipated,” Novo Nordsk mentioned in an announcement.

One other blow was handled earlier this week after a Dilayer court ruled Patents of the VIATRIS are being supplied for the VIATRIS, which is at the moment ready for the approval of the US Meals and Drug Administration (FDA), doesn’t violate Wegovy.